NCT06943573View on ClinicalTrials.gov

Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Bipolar II Depression
Interventions
DRUG

psilocybin (25 mg)

Single-dose psilocybin (25 mg)-assisted therapy (PAT)

DRUG

psilocybin 1mg micro-dose

Single dose active placebo psilocybin-assisted therapy

Trial Locations (3)

V6T 1Z3

Djavad Mowafaghian Centre for Brain Health, Vancouver

K1H 8L6

Department of Psychiatry, University of Ottawa, The Ottawa Hospital, Ottawa

M5T 2S8

Department of Psychiatry, University of Toronto, University Health Network,, Toronto

All Listed Sponsors
lead

Lakshmi N Yatham

OTHER